GenXys, a health tech company focused on pharmacogenetic enhanced prescribing automation software, is pleased to announce that it has closed an oversubscribed seed round at $3 million. Led by Green Shield Canada, (GSC), with key investors including TELUS Ventures, Esplanade Ventures, Nimbus Synergies, and the Business Development Bank of Canada (BDC Capital).
Please proceed with registration and ordering once you have received your approval letter and promotional code from GSC.